SecBot SecBot
8-K ·Filed Jul 13, 2026

ESPR

Esperion Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonimmediate Processed4mo ago SEC0001104659-26-082926
Killer combo: M&A completed + management change
Actionable Insight ▲ Bullish

ESPR common stock will cease trading on Nasdaq; holders should expect to receive $3.16 per share in cash plus one CVR per share. The CVRs are non-transferable and contingent on achieving sales milestones for NEXLETOL/NEXLIZET (2027) and ENBUMYST (through 2030). Monitor future announcements regarding milestone achievement for potential CVR value realization.

DirectionBullish
Confidencehigh
Horizonimmediate

Drugs in focus

ESPR drug pipeline →

NEXLIZET

● Neutral Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercialized (since February 2020)
Next catalyst
None dated

What to watchESPR common stock has been acquired by ARCHIMED at $3.16/share with the deal closing July 13, 2026. Holders received one non-transferable Contingent Value Right (CVR) per share, entitling them to potential milestone payments tied to NEXLETOL/NEXLIZET U.S. net sales (starting 2027) and ENBUMYST (through 2030). There is no further tradeable equity vehicle, the stock will be delisted.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per share in cash plus one contingent value right (CVR) per share, representing up to $100M in aggregate milestone payments. The merger triggers delisting from Nasdaq, a change of control, replacement of the board, and termination of the prior credit agreement with new debt financing from BioPharma Credit.

Key Financial Metrics

Deal Value
$1.1B
Deal Type
acquisition

Key Facts

  • Merger completed on July 13, 2026; each share converted into $3.16 cash plus one CVR
  • Total cash consideration approximately $1.1 billion, funded by equity and debt from BioPharma Credit
  • CVRs entitle holders to up to $100M aggregate contingent payments tied to U.S. net sales milestones for NEXLETOL/NEXLIZET (bempedoic acid) and ENBUMYST (bumetanide)
  • Common stock to be delisted from Nasdaq; Form 15 to be filed to suspend SEC reporting obligations
  • All prior directors resigned; Justin Bateman and Ankit Pareek appointed as new directors
  • Prior credit agreement with GLAS USA LLC terminated and repaid in full
  • New loan agreement entered with BioPharma Credit PLC and affiliates

Financial Impact

Cash consideration of approximately $1.1 billion plus CVRs with up to $100M in aggregate milestone payments

cash consideration per sharecontingent milestone paymentsdebt refinancing

Risk Factors

  • CVR milestones may not be achieved, resulting in no additional payments
  • No further liquidity for common stock after delisting
  • CVRs are non-transferable and cannot be traded

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-082926
Document: tm2620034d3_ex3-2.htm0001104659-26-082926
Document: tm2620034d3_8k.htm0001104659-26-082926
Document: tm2620034d3_ex4-1.htm0001104659-26-082926
Document: tm2620034d3_ex3-1.htm0001104659-26-082926
Document: 0001104659-26-082926-index-headers.html0001104659-26-082926
Document: 0001104659-26-082926-index.html0001104659-26-082926
Document: 0001104659-26-082926.txt0001104659-26-082926

Track record

21 reports on ESPR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
  2. Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
  3. Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
  4. Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
  5. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  6. Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
  7. Jul 13, 202618w ago 25-NSE Bullish 7/10 Entry $3.19 No price data
  8. Jul 13, 202618w ago 8-K Bullish 7/10 Viewing Entry $3.19 No price data
  9. Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
  10. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026